Eli Lilly (LLY) Price Target Increased to $1,400, Analysts See 25% Upside
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn September 15, Berenberg upgraded Eli Lilly and Company (NYSE: LLY) from Hold to Buy, raising its price target from $1,220 to $1,400. Analysts predict about 25% upside, citing strong investment returns and growth in obesity treatments. Eli Lilly's recent investments total around $60 billion, with more than 25 business development deals made this year. The company faces risks, including US drug pricing reforms and potential competition that may impact growth. This matters to investors as higher price targets suggest analysts expect the stock to perform well.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Related News
Tempus AI (TEM) Revenue Outlook Boosted by Morgan Stanley Insight
Sep 17
Aeluma (ALMU) Reports Q4 2026 Earnings and Market Insights
Sep 17
BioMarin Targets $100 with Bullish Call Spread by April 2027
Sep 17
Oracle (ORCL) Reports $664 Billion Backlog-to-Revenue Ratio in 2026
Sep 17